Table 1.
Characteristics of 251 patients undergoing first induction chemotherapy for acute myeloid leukemia.
| Variable | n (%) |
|---|---|
| Male | 138 (55) |
| Female | 113 (45) |
| Age, years (mean ± std dev) | 61.8 ± 14 |
| Hematologic malignancy | |
| Primary AML | 148 (59) |
| MDS with transformation to AML | 76 (30) |
| Therapy-related AML | 27 (11) |
| Comorbid conditions | |
| Diabetes mellitus | 37 (15) |
| Coronary artery disease | 31 (12) |
| Chronic obstructive pulmonary disease | 24 (10) |
| Congestive heart failure | 22 (9) |
| Rheumatologic disease | 11 (4) |
| Interstitial lung disease | 7 (3) |
| Heart transplant | 2 (1) |
| Induction chemotherapy regimens (no.) | |
| 1 | 157 (63) |
| ≥2 | 94 (37) |
| Allogeneic hematopoietic cell transplant | 75 (30) |
| Matched related | 27 |
| Matched unrelated | 43 |
| Haploidentical | 4 |
| Mismatched | 1 |
| Graft-versus-host disease treatment | 52 |
| Corticosteroids * | 37 |
| Tacrolimus | 16 |
| Anti-thymocyte globulin | 4 |
| Methotrexate | 3 |
AML: acute myeloid leukemia, MDS: myelodysplastic syndrome; * defined as ≥ 0.3 mg/kg/day of prednisone equivalent.